Aztreonam News and Research

RSS
Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan and AstraZeneca partner to develop, commercialize ATM-AVI for MBL-producing pathogens

Allergan and AstraZeneca partner to develop, commercialize ATM-AVI for MBL-producing pathogens

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

Rising shortages of key antibiotics raise serious concerns about effects on patient care

Rising shortages of key antibiotics raise serious concerns about effects on patient care

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

FDA designates Rib-X's delafloxacin as QIDP for acute bacterial skin and skin structure infections

FDA designates Rib-X's delafloxacin as QIDP for acute bacterial skin and skin structure infections

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

New in vitro study results show that wound dressing with ionic silver kills strains of highly-resistant bacteria

New in vitro study results show that wound dressing with ionic silver kills strains of highly-resistant bacteria

FDA approves Teflaro for treatment of community-acquired bacterial pneumonia

FDA approves Teflaro for treatment of community-acquired bacterial pneumonia

Teflaro receives FDA approval for treatment of bacterial infections

Teflaro receives FDA approval for treatment of bacterial infections

Gilead announces results from Phase III clinical trial of Cayston, TIS in cystic fibrosis patients

Gilead announces results from Phase III clinical trial of Cayston, TIS in cystic fibrosis patients

Gilead Sciences third quarter total revenues increase 8% to $1.94 billion

Gilead Sciences third quarter total revenues increase 8% to $1.94 billion

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

APP Pharmaceuticals receives FDA approval to market Aztreonam for Injection, USP

APP Pharmaceuticals receives FDA approval to market Aztreonam for Injection, USP

Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010

Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Gilead Sciences receives FDA approval for new inhaled antibiotic in treatment of CF

Gilead Sciences receives FDA approval for new inhaled antibiotic in treatment of CF

Heilongjiang Tianlong Pharmaceutical changes R&D focus to antibiotics and cardiac drugs

Heilongjiang Tianlong Pharmaceutical changes R&D focus to antibiotics and cardiac drugs

FDA Drugs Advisory Committee recommends approval for Gilead Sciences' aztreonam for inhalation solution

FDA Drugs Advisory Committee recommends approval for Gilead Sciences' aztreonam for inhalation solution

Anti-Infective Drugs Advisory Committee to review aztreonam for inhalation solution

Anti-Infective Drugs Advisory Committee to review aztreonam for inhalation solution